Certara (NASDAQ:CERT) Updates FY 2026 Earnings Guidance

Certara (NASDAQ:CERT) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided EPS guidance of 0.350-0.410 for the period, compared to the consensus EPS estimate of 0.360. The company issued revenue guidance of $395.0 million-$405.0 million, compared to the consensus revenue estimate of $398.9 million.

Analyst Ratings Changes

A number of equities research analysts have recently commented on CERT shares. BMO Capital Markets reduced their target price on shares of Certara from $7.00 to $6.00 and set a “market perform” rating for the company in a research report on Tuesday, May 12th. Robert W. Baird cut their price target on Certara from $7.00 to $6.00 and set a “neutral” rating for the company in a report on Tuesday, May 12th. KeyCorp lowered their price objective on Certara from $10.00 to $8.00 and set an “overweight” rating on the stock in a research note on Monday, April 13th. Morgan Stanley cut their target price on Certara from $11.00 to $10.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 12th. Finally, Barclays dropped their price target on shares of Certara from $8.00 to $6.50 and set an “equal weight” rating for the company in a research report on Tuesday, May 12th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $8.85.

Certara Stock Up 3.0%

CERT stock opened at $6.55 on Wednesday. The company has a 50-day moving average of $5.59 and a two-hundred day moving average of $6.88. Certara has a 52-week low of $4.45 and a 52-week high of $13.88. The stock has a market capitalization of $1.02 billion, a price-to-earnings ratio of -65.50 and a beta of 1.49. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.88 and a quick ratio of 1.88.

Certara (NASDAQ:CERT) last released its quarterly earnings data on Monday, May 11th. The company reported $0.09 EPS for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). Certara had a negative net margin of 3.60% and a positive return on equity of 3.52%. The company had revenue of $106.92 million during the quarter, compared to the consensus estimate of $106.13 million. During the same quarter in the prior year, the company posted $0.14 EPS. The company’s revenue for the quarter was up .8% compared to the same quarter last year. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. As a group, equities research analysts anticipate that Certara will post 0.24 EPS for the current year.

Hedge Funds Weigh In On Certara

Institutional investors have recently bought and sold shares of the company. AQR Capital Management LLC purchased a new stake in shares of Certara during the first quarter worth $259,000. Goldman Sachs Group Inc. raised its stake in Certara by 65.6% in the first quarter. Goldman Sachs Group Inc. now owns 228,996 shares of the company’s stock valued at $2,267,000 after purchasing an additional 90,724 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Certara by 13.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 299,528 shares of the company’s stock worth $2,965,000 after acquiring an additional 35,954 shares during the last quarter. Jane Street Group LLC increased its holdings in shares of Certara by 17.1% in the first quarter. Jane Street Group LLC now owns 277,054 shares of the company’s stock worth $2,743,000 after buying an additional 40,463 shares during the period. Finally, JPMorgan Chase & Co. grew its position in shares of Certara by 29.3% in the 2nd quarter. JPMorgan Chase & Co. now owns 93,057 shares of the company’s stock worth $1,089,000 after buying an additional 21,099 shares during the last quarter. Hedge funds and other institutional investors own 73.96% of the company’s stock.

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.